For richer charts and full features, open SpikePanel on desktop.
Graded daily on value B+, growth B-, profitability A+, momentum A-, revisions A-. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $EXEL are available with SpikePanel Pro.
Key events, in time order
Revenue ~$659M, EPS $0.94 beat; pipeline advances
Regulatory delay affects timeline for zanzalintinib combo approval
FDA accepts NDA for zanzalintinib+atezolizumab in mCRC; PDUFA date Dec 3, 2026
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice